Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00236197 · ClinicalTrials.gov registry record · Phase 3
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
A Phase 3 study of Heartburn, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 619
- Enrollment target
- 1
- Study location
NCT00236197: Completed Phase 3 study of Heartburn, sponsored by Eisai.
NCT00236197 is a Phase 3 study of Heartburn that has completed, run by Eisai. The registered enrollment target is 619 participants, above the 351-participant average among 9 other Heartburn trials with a reported enrollment target (76% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00236197, a Phase 3 study of Heartburn, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 619 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the safety and efficacy of rabeprazole 10 mg in treating frequent heartburn.
Primary Outcome
The difference in complete relief within the first 24 hours between treatment and placebo in ITT was tested using a continuity corrected chi-square test withput adjustment for baseline severity.
Conditions Studied
Interventions
- DRUG placebo
- DRUG rabeprazole sodium
Study Locations (1)
New York
- New York Center For Clinical Research - Lake Success
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 619 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
What the finished NCT00236197 record still lists
NCT00236197 is an interventional study that assigns participants to a tested intervention. The registered 619 participants enrollment target is mid-sized for trials with a published cap, above the 351-participant average among 9 other Heartburn trials with a reported enrollment target (76% higher).
The record links to 1 condition, with Heartburn appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00236197 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00236197 about?
NCT00236197 is a clinical study titled "E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers". The purpose of this study is to investigate the safety and efficacy of rabeprazole 10 mg in treating frequent heartburn.
What is the current status of trial NCT00236197?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 619 participants. The study started on 2005-10. Estimated completion is 2008-06.
What conditions does trial NCT00236197 study?
This clinical trial studies the following conditions: Heartburn.
What interventions are being tested in trial NCT00236197?
The interventions under investigation include: placebo (DRUG), rabeprazole sodium (DRUG).
Who is sponsoring clinical trial NCT00236197?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00236197 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heartburn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00236197's enrollment target sits among peer trials
619 3rd of 9 higher than 7 of 9 other Heartburn trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heartburn trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
-
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
COMPLETED · Phase 3
-
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
COMPLETED · Phase 3
-
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
COMPLETED · Phase 3
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- NCT05538910 · 620 participants · NA
Defining Neurobiological Links Between Substance Use and Mental Illness
- NCT05822466 · 620 participants · NA
Virtual Tai ji Quan Exercise to Prevent Falls in Older Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia